Moreover, CYLD is also able to inhibit HDAC6, a member of the HDAC family whose major substrate is α-tubulin, has become a target for drug development to treat cancer due to its major contribution in oncogenic cell transformation [60]. This evidence concerns the gene HDAC6 and cancer.